LumiraDx

18 articles with LumiraDx

• LumiraDx Reports Second Quarter 2022 ResultsStrong Pipeline Progress and Commercialization Priorities for Newly Authorized Products

  8/18/2022

  LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced operational and financial results for the second quarter ended June 30, 2022.

• LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18

  8/11/2022

  LumiraDx Limited  (Nasdaq:  LMDX ), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 18th, 2022.

• LumiraDx Announces Pricing of Public Offering of Common Shares and Concurrent Private Placement

  7/21/2022

  LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced the pricing of its underwritten public offering of 43,000,000 common shares at a price to the public of $1.75 per share.

• LumiraDx Announces Proposed Public Offering of Common Shares

  7/19/2022

  LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced that it has commenced an underwritten public offering of 40,000,000 common shares.

• LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete

  6/8/2022

  LumiraDx Limited announced that it has achieved CE Mark for two new Fast Lab Solutions molecular tests, including Dual-Target SARS-CoV-2 STAR Complete and SARS-CoV-2 & Flu A/B RNA STAR Complete.

• LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test

  6/2/2022

  LumiraDx Limited announced it has expanded its cardiovascular offering with a CE Mark for its new NT-proBNP test to aid in the diagnosis of CHF and an updated CE Mark for its D-Dimer test to now rule out venous thromboembolism in symptomatic patients.

• LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform

  5/26/2022

  LumiraDx Limited, a next-generation point of care diagnostics company, announced its HbA1c test has achieved CE Marking.

• LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test

  5/20/2022

  LumiraDx Limited, a next-generation point of care diagnostics company, announced that its rapid COVID-19 antigen assay, LumiraDx SARS-CoV-2 Ag Test has successfully received the Emergency Use Listing by the World Health Organization in their latest response effort to combat COVID-19.

• LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking

  5/19/2022

  LumiraDx Limited, a next-generation point of care diagnostics company, announced its SARS-CoV-2 Ag Ultra Test achieved CE Marking.

• LumiraDx Reports First Quarter 2022 Results

  5/11/2022

  LumiraDx Limited, a next-generation point of care diagnostics company, announced financial and operational results for the first quarter ended March 31, 2022.

• LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 11

  4/29/2022

  LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its first quarter financial results on Wednesday, May 11, 2022.

• LumiraDx Reports Fourth Quarter and Full Year 2021 Results

  3/10/2022

  LumiraDx Limited, a next-generation point of care diagnostics company, announced financial and operational results for the fourth quarter and full year ended December 31, 2021.

• LumiraDx Announces Pricing of $56.5 Million Convertible Notes Offering

  3/1/2022

  LumiraDx Limited announced that it entered into privately negotiated subscription agreements with certain investors pursuant to which LumiraDx agreed to sell and the investors agreed to purchase from LumiraDx $56.5 million aggregate principal amount of 6.00% Convertible Senior Subordinated Notes due 2027.

• LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant

  1/14/2022

  Results from ongoing testing and monitoring of COVID-19 variants shows the rapid microfluidic test detects Omicron at a comparable sensitivity to other variants.

• LumiraDx CRP Test Achieves CE Marking

  1/11/2022

  LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its C-reactive protein (CRP) Test has achieved CE Marking.

• LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B Microfluidic Antigen Test

  1/11/2022

  LumiraDx, a next-generation point of care diagnostics company, announced preliminary results for the fourth quarter of 2021 as well as expected full-year revenue.

• LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking

  12/23/2021

  LumiraDx, a next-generation point of care diagnostics company, announced its SARS-CoV-2 & Flu A/B Antigen Test has achieved CE Marking.

• LumiraDx Fast Lab Solutions Partners with Audere for At-Home Self- Collection Solution for use with SARS-CoV-2 RNA STAR Complete

  12/15/2021

  LumiraDx (Nasdaq: LMDX) today announced a partnership with digital health non-profit Audere, to offer a self-collected COVID-19 nasal specimen collection kit that has been authorized for use with the LumiraDx SARS-CoV-2 RNA STAR Complete assay to process self-collected samples.